TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria
Brief Summary: The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.


Options:
A: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A
B: Arm Label: A,AIIA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan and enalapril | Arm Label: A, ACE-I; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Arm Label: C, AIIA; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Arm Label: C, ACE; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Intervention Type: DRUG; Name: Candesartan and enalapril; Assigned to Arm(s): A,AIIA | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): A, ACE-I | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): C, AIIA | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): C, ACE
C: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Study to Assess the Effect of Vitamin D3 8400IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Aged 70 Years or Older
Brief Summary: This study will assess the effectiveness of an investigational drug in elderly subjects with low vitamin D levels.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cure | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: MK0822A; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): N/A
D: Arm Label: 90 Hz whole-body vibration; Type: EXPERIMENTAL; Interventions: Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform | Arm Label: 30 Hz whole-body vibration; Type: EXPERIMENTAL; Interventions: Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Juvent 1000 Dynamic Motion Therapy (DMT) Platform; Assigned to Arm(s): 90 Hz whole-body vibration | Intervention Type: DEVICE; Name: Juvent 1000 Dynamic Motion Therapy (DMT) Platform; Assigned to Arm(s): 30 Hz whole-body vibration

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study
Brief Summary: The purpose of this study is to compare the efficacy, safety and tolerance of the drugs Lamotrigine and Levetiracetam in the initial monotherapy of patients with newly diagnosed epilepsy.


Options:
A: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Older Antepileptic Drugs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine Controlled Release (CBZ-CR), Drug: Valproate Extended Release | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine Controlled Release (CBZ-CR); Assigned to Arm(s): Older Antepileptic Drugs | Intervention Type: DRUG; Name: Valproate Extended Release; Assigned to Arm(s): Older Antepileptic Drugs
B: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
C: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study
Brief Summary: The purpose of this study is to compare the efficacy, safety and tolerance of the drugs Lamotrigine and Levetiracetam in the initial monotherapy of patients with newly diagnosed epilepsy.


Options:
A: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
C: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250
D: Intervention Type: DRUG; Name: phenobarbitone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carbamazepine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study
Brief Summary: The purpose of this study is to compare the efficacy, safety and tolerance of the drugs Lamotrigine and Levetiracetam in the initial monotherapy of patients with newly diagnosed epilepsy.


Options:
A: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
B: Arm Label: Lacosamide; Type: EXPERIMENTAL; Interventions: Drug: Lacosamide | Arm Label: Carbamazepine-Controlled Release (CBZ-CR); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine-Controlled Release | Intervention Type: DRUG; Name: Lacosamide; Assigned to Arm(s): Lacosamide | Intervention Type: DRUG; Name: Carbamazepine-Controlled Release; Assigned to Arm(s): Carbamazepine-Controlled Release (CBZ-CR)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
D: Arm Label: Lacosamide; Type: EXPERIMENTAL; Interventions: Drug: Lacosamide | Arm Label: Carbamazepine-Controlled Release (CBZ-CR); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine-Controlled Release (CBZ-CR) | Intervention Type: DRUG; Name: Lacosamide; Assigned to Arm(s): Lacosamide | Intervention Type: DRUG; Name: Carbamazepine-Controlled Release (CBZ-CR); Assigned to Arm(s): Carbamazepine-Controlled Release (CBZ-CR)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computerized Physical Activity Promotion in Primary Care
Brief Summary: This study will test the efficacy of providing primary care physicians and their patients with computer-tailored information, based on patients' responses to survey questions. The health education messages are designed to encourage patients to become physically active and to encourage physicians to counsel their patients about exercise.


Options:
A: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
B: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Phone counseling with written materials | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Phone counseling with written materials; Assigned to Arm(s): Intervention Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computerized Physical Activity Promotion in Primary Care
Brief Summary: This study will test the efficacy of providing primary care physicians and their patients with computer-tailored information, based on patients' responses to survey questions. The health education messages are designed to encourage patients to become physically active and to encourage physicians to counsel their patients about exercise.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet and print-based interventions; Assigned to Arm(s): N/A
B: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
D: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computerized Physical Activity Promotion in Primary Care
Brief Summary: This study will test the efficacy of providing primary care physicians and their patients with computer-tailored information, based on patients' responses to survey questions. The health education messages are designed to encourage patients to become physically active and to encourage physicians to counsel their patients about exercise.


Options:
A: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group
B: Arm Label: PEPAF; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental Programme for Physical Activity Promotion | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Experimental Programme for Physical Activity Promotion; Assigned to Arm(s): PEPAF | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
C: Arm Label: PA intervention and Maintenance plus; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance plus | Arm Label: PA intervention and Maintenance regular; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance regular | Arm Label: Pedometer; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control (pedometer only) | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance plus; Assigned to Arm(s): PA intervention and Maintenance plus | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance regular; Assigned to Arm(s): PA intervention and Maintenance regular | Intervention Type: BEHAVIORAL; Name: Control (pedometer only); Assigned to Arm(s): Pedometer
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).
Brief Summary: The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.


Options:
A: Arm Label: novel nutritional formula; Type: EXPERIMENTAL; Interventions: Other: medical food with EPA and GLA, vitamins and minerals | Arm Label: Control nutritional product; Type: ACTIVE_COMPARATOR; Interventions: Other: medical food minus EPA and GLA, antioxidant vitamins/minerals | Intervention Type: OTHER; Name: medical food with EPA and GLA, vitamins and minerals; Assigned to Arm(s): novel nutritional formula | Intervention Type: OTHER; Name: medical food minus EPA and GLA, antioxidant vitamins/minerals; Assigned to Arm(s): Control nutritional product
B: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).
Brief Summary: The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.


Options:
A: Intervention Type: DRUG; Name: budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Budesonide/formoterol; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).
Brief Summary: The purpose of this study is to compare the efficacy and safety of a variable dose of Symbicort with a high fixed maintenance dose of another asthma medication, Seretide, in the treatment of asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate or formoterol/budesonide | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate or formoterol/budesonide; Assigned to Arm(s): Arm 1
C: Arm Label: Flutiform 250/10 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 250/10 micrograms | Arm Label: Flutiform 50/5 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 50/5 micrograms | Arm Label: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Arm Label: Flixotide pMDI 250 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 micrograms | Intervention Type: DRUG; Name: Flutiform 250/10 micrograms; Assigned to Arm(s): Flutiform 250/10 micrograms | Intervention Type: DRUG; Name: Flutiform 50/5 micrograms; Assigned to Arm(s): Flutiform 50/5 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Assigned to Arm(s): Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 micrograms; Assigned to Arm(s): Flixotide pMDI 250 micrograms
D: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome
Brief Summary: The purpose of this study is to compare the effects of pitavastatin and atorvastatin on coronary plaque volume in patients with acute coronary syndrome and to clarify the relationship between coronary plaque volume, serum lipids, and inflammation markers in order to determine the significance of intensive lipid lowering therapy in patients with acute coronary syndrome in Japan.


Options:
A: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rosuvastatin calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The IMAGE Study is a cluster randomised trial of a structural intervention for the prevention of HIV and gender based violence being conducted in South Africa.


Options:
A: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Monthly placebo | Arm Label: Treatment arm; Type: EXPERIMENTAL; Interventions: Drug: Monthly antibiotic | Intervention Type: DRUG; Name: Monthly antibiotic; Assigned to Arm(s): Treatment arm | Intervention Type: DRUG; Name: Monthly placebo; Assigned to Arm(s): Sugar pill
B: Intervention Type: BEHAVIORAL; Name: In-school Sexual Health Education; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth-friendly health services; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth condom promotion & distribution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Community activities related to adolescent sexual health; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Intervention with Microfinance for AIDS and Gender Equity; Assigned to Arm(s): N/A

Answer: D